Drug Profile
Research programme: antibody therapeutics - Five Prime/Ligand Pharmaceuticals
Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Five Prime Therapeutics; Ligand Pharmaceuticals
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Unspecified in USA (Parenteral)
- 16 Apr 2021 Five Prime Therapeutics has been acquired by Amgen
- 06 Apr 2018 Preclinical trials in Undefined indication in USA (parenteral) (Ligand Pharmaceuticals pipeline, April 2018)